Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
GH Research PLC GHRS
$10.57
+$0.42 (3.93%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
462985120.00000000
-
week52high
17.41
-
week52low
5.70
-
Revenue
0
-
P/E TTM
-197
-
Beta
0.00000000
-
EPS
-0.46000000
-
Last Dividend
0.00000000
-
Next Earnings Date
17 мая 2023 г. в 04:00
Описание компании
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 16 авг 2022 г. | |
| Roth Capital | Buy | 16 июн 2022 г. | |
| Canaccord Genuity | Buy | Buy | 13 апр 2022 г. |
| JMP Securities | Outperform | 20 июл 2021 г. | |
| Cowen & Co. | Outperform | 20 июл 2021 г. | |
| EF Hutton | Buy | 16 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
The 7 Most Promising Psychedelic Stocks to Buy in February
InvestorPlace
05 февр 2023 г. в 14:30
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
Psychedelic Sunday: Competitive Strategies
Seeking Alpha
15 янв 2023 г. в 11:45
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
7 Short-Squeeze Stocks for Bold Contrarians to Consider
InvestorPlace
21 ноя 2022 г. в 12:22
Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.
New Strong Buy Stocks for October 24th
Zacks Investment Research
24 окт 2022 г. в 09:02
BXRX, WOLF, GHRS, RKDA and BHR have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2022.
Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?
Zacks Investment Research
14 сент 2022 г. в 11:13
The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.